New chairs at SomaLogic, Anjarium
Plus Dechamps becomes CEO at Bioxodes, and updates from Abalos, M2Gen and Orion
AI-based proteomics company SomaLogic Inc. (NASDAQ:SLGC) appointed board member Troy Cox as executive chair, succeeding Chuck Lillis. Cox was president and CEO of Foundation Medicine Inc., before which he was SVP and officer at Genentech Inc. Lillis, who served as chair for three years, will remain on the board.
Gaurav Shah became chair at Anjarium Biosciences AG, a non-viral gene therapy company. Shah was founding CEO of Rocket Pharmaceuticals Inc. (NASDAQ:RCKT), an AAV and lentiviral-based gene therapy company, and venture partner at RTW Investments. Anjarium also appointed Douglas Fambrough, former president and CEO of Dicerna Pharmaceuticals Inc., to its board...